ARL6IP5 and breast carcinoma: Arsenic trioxide up-regulates the expression of ARL6IP5 by stimulating the production of reactive oxygen species in a dose-dependent manner, and ARL6IP5 induces apoptosis and loss of mitochondrial transmembrane potential in breast cancer cells [61].